Recent Posts
- NeoProgen receives approval from U.S. FDA for a Phase I Study of The Safety And Early Efficacy of Intravenous Allogeneic Neonatal Mesenchymal Cells (nMSCs) In Chronic Ischemic Heart Failure
- NeoProgen, Inc. Receives First Granted Patent for Method to Treat Cardiac Conditions using Neonatal Heart-derived Medicinal Signaling Cells (nMSCs) and/or their Secretomes/Exosomes from the US Patent Office
- Secretome Therapeutics Presents Scientific Poster on the Essential Role of Complete Secretome in Regenerative Cell Therapy at ISSCR 2023 Annual Meeting
- Secretome Therapeutics Announces Appointment of Angela Shen, M.D., M.B.A., to Board of Directors
- Comparative efficacy and mechanism of action of cardiac progenitor cells after cardiac injury